Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on Formycon AG (FYB – Research Report) on January 7 and set a price target of ...

Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...

FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

Thanks to our development expertise and agility, we are ideally placed to position Formycon AG as a leading independent provider of high-quality biosimilars in the market,” says Dr. Stefan ...

Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr. Die Informationen auf dem Portal BörsenNEWS.de ...

Equity Ratio: Approximately 60%, indicating a strong financial position. Formycon AG (XTER:FYB) achieved two FDA approvals and two positive CHMP opinions for its biosimilars, FYB202 and FYB203, in a ...

Approved by Health Canada for Both Subcutaneous and Intravenous Formulations to Treat Serious Inflammatory Diseases Health Canada Joins the FDA and the European Commission in Granting Regulatory ...